Dr. Andrew Blauvelt is the President of the Oregon Medical Research Center, a small business dedicated to performing high-quality clinical research studies in dermatology. He received his undergraduate degree in electrical engineering at Purdue University, his medical degree at Michigan State University, and a healthcare MBA at Oregon Health & Science University (OHSU). Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Steve Katz at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland VA Medical Center (Chief). Dr. Blauvelt’s research and clinical expertise has been in Langerhans cell biology, T cell immunology, virology, psoriasis, and atopic dermatitis. He has published over 300 papers and spoken across the country and world on these topics. Within psoriasis research, his laboratory has published key papers on the role of IL-23/Th17 biology in psoriasis; in recent years, he has been the international lead investigator on a number of important clinical trials, including PSTELLAR, FEATURE, IXORA-R, VOYAGE 1, IMMhance, CHRONOS, ECZTEND, JADE REGIMEN, and HEADS UP. Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council, the International Eczema Council, and the Scientific Advisory Committee of the National Psoriasis Foundation. In 2021, he made the list of Highly Cited Researchers, representing the top 1% of cited scientists in the world.